PGCP Activators

Plasma glutamate carboxypeptidase (PGCP), also known as prostate-specific membrane antigen (PSMA), is an enzyme that has gained notable attention particularly in the context of prostate cancer. It is encoded by the gene FOLH1 (folate hydrolase 1). PGCP is a type II transmembrane glycoprotein that belongs to the M28 peptidase family and exhibits both folate hydrolase and N-acetylated-alpha-linked acidic dipeptidase (NAALADase) activity.The enzyme is expressed in various tissues but is most notably known for its high expression in the prostate, particularly in prostate cancer cells, where it is significantly upregulated. PGCP/PSMA's enzymatic function involves the hydrolysis of the bond between glutamate and its substrates, including folate and the neuropeptide N-acetyl-aspartyl-glutamate (NAAG), which plays a role in neurotransmission. By cleaving NAAG, it regulates the levels of glutamate, an important neurotransmitter in the central nervous system, thus implicating it in neurological functions and potentially in neurological disorders.

In cancer biology, PGCP/PSMA is recognized for its role in tumor progression and as a biomarker for prostate cancer. Its expression on the surface of prostate cancer cells allows for its use in diagnostic imaging and targeted therapies, including radioimmunotherapy and antibody-drug conjugates. The enzyme's folate hydrolase activity is also linked to the regulation of folate availability, which is critical for DNA synthesis and repair, suggesting a role in cell proliferation.While PGCP/PSMA has been most extensively studied in the context of prostate cancer, its expression and activity in other tissues suggest a broader physiological significance, which warrants further investigation.